TY - JOUR
T1 - American Society for Gastrointestinal Endoscopy-European Society of Gastrointestinal Endoscopy guideline on primary endoscopic bariatric and metabolic therapies for adults with obesity
AU - Jirapinyo, Pichamol
AU - Hadefi, Alia
AU - Thompson, Christopher C
AU - Patai, Árpád V
AU - Pannala, Rahul
AU - Goelder, Stefan K
AU - Kushnir, Vladimir
AU - Barthet, Marc
AU - Apovian, Caroline M
AU - Boskoski, Ivo
AU - Chapman, Christopher G
AU - Davidson, Paul
AU - Donatelli, Gianfranco
AU - Kumbhari, Vivek
AU - Hayee, Bu
AU - Esker, Janelle
AU - Hucl, Tomas
AU - Pryor, Aurora D
AU - Maselli, Roberta
AU - Schulman, Allison R
AU - Pattou, Francois
AU - Zelber-Sagi, Shira
AU - Bain, Paul A
AU - Durieux, Valérie
AU - Triantafyllou, Konstantinos
AU - Thosani, Nirav
AU - Huberty, Vincent
AU - Sullivan, Shelby
PY - 2024
Y1 - 2024
N2 - This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥ 30 kg/m2, or with a BMI of 27.0-29.9 kg/m2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
AB - This joint ASGE-ESGE guideline provides an evidence-based summary and recommendations regarding the role of endoscopic bariatric and metabolic therapies (EBMTs) in the management of obesity. The document was developed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework. It evaluates the efficacy and safety of EBMT devices and procedures that currently have CE mark or FDA-clearance/approval, or that had been approved within five years of document development. The guideline suggests the use of EBMTs plus lifestyle modification in patients with a BMI of ≥ 30 kg/m2, or with a BMI of 27.0-29.9 kg/m2 with at least 1 obesity-related comorbidity. Furthermore, it suggests the utilization of intragastric balloons and devices for endoscopic gastric remodeling (EGR) in conjunction with lifestyle modification for this patient population.
KW - Endoscopy
KW - Gastrointestinal
KW - Endoscopy
KW - Gastrointestinal
UR - https://publicatt.unicatt.it/handle/10807/310378
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85192004059&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85192004059&origin=inward
U2 - 10.1016/j.gie.2023.12.004
DO - 10.1016/j.gie.2023.12.004
M3 - Article
SN - 0016-5107
VL - 99
SP - 867
EP - 885
JO - Gastrointestinal Endoscopy
JF - Gastrointestinal Endoscopy
IS - 6
ER -
